Thienopyrimidines as β3-adrenoceptor agonists: Hit-to-lead optimization

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 20, 2010, Pages 6108-6115

  Tasler, Stefan ^a   Baumgartner, Roland ^a   Ammendola, Astrid ^a   Schachtner, Josef ^a   Wieber, Tanja ^a   Blisse, Marcus ^a   Rath, Sandra ^a   Zaja, Mirko ^a   Klahn, Philipp ^a   Quotschalla, Udo ^b   Ney, Peter ^b  

^a 4SC AG   (Germany)

^b UCB PHARMA   (Belgium)

Author keywords

3 Adrenergic receptor; Adrenoceptor; GPCR; Molecular modeling; vHTS

Indexed keywords

ARYLOXYPROPANOLAMINE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; LEAD; PROPANOLAMINE DERIVATIVE; PYRIMIDINE; THIENOPYRIMIDINE; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVITY; HUMAN; MOLECULAR MODEL; PHARMACOPHORE; PROCESS OPTIMIZATION;

ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; CELL LINE; CELL SURVIVAL; DRUG DESIGN; HUMANS; PROTEIN BINDING; PYRIMIDINES; RECEPTORS, ADRENERGIC, BETA-3;

EID: 77956896566     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.08.039     Document Type: Article

References (29)

1. M.G. Ursino, V. Vasina, E. Raschi, F. Crema, and F. De Ponti Pharmacol. Res. 59 2009 221
2. T. Wu, and L. Wang Med. Hypotheses 69 2007 1114
3. S. Lee, R.H.G. Schwinger, and K. Brixius Pflugers Arch. Eur. J. Physiol. 455 2008 767
4. J.R.S. Arch Naunyn-Schmied. Arch. Pharmacol. 378 2008 225
5. Information gathered from Thomson Reuters iddb3 database, MedTRACK and www.clinicaltrials.gov.
6. P. Tyagi, V. Tyagi, N. Yoshimura, M. Chancellor, and O. Yamaguchi Drugs Future 34 2009 635
7. C.P. Kordik, and A.B. Reitz J. Med. Chem. 42 1999 181
8. S. Tasler, R. Baumgartner, A. Aschenbrenner, A. Ammendola, K. Wolf, T. Wieber, J. Schachtner, M. Blisse, U. Quotschalla, and P. Ney Bioorg. Med. Chem. Lett. 20 2010 3399
9. i = 841 and 24 nM, respectively. No functional data is presented.
10. All aryloxypropanolamine derivatives were tested as racemates. For a further lead optimization process, the (S)-enantiomers proved to be more active than the respective (R)-enantiomers.
11. 50 determinations, which were based on concentration curves using eight concentrations (half-logarithmic) in duplicate.
12. 50 values, respectively, were determined by dose-response curves based on seven concentrations (logarithmic) determined in duplicate.
13. The term 'affinity' is strictly used for the description of binding data, whereas 'activity' refers to functional data from cellular assays throughout this Letter.
14. F.J. Ehlert Naunyn-Schmied. Arch. Pharmacol. 377 2008 549
15. M. Lutz, and T. Kenakin Quantitative Molecular Pharmacology and Informatics in Drug Discovery 1999 Wiley & Sons Chichester Chapter 3.6, p 86ff; ISBN 0 471 98861 8
16. N.A. Hanania, A. Sharafkhaneh, R. Barber, and B.F. Dickey Am. J. Respir. Crit. Care Med. 165 2002 1353
17. In analogy to, for example: S. Wagner, K. Kopka, M.P. Law, B. Riemann, V.W. Pike, O. Schober, and M. Schäfers Bioorg. Med. Chem. 12 2004 4117
18. E. Elzein, K. Shenk, P. Ibrahim, T. Marquart, S. Kerwar, S. Meyer, H. Ahmed, D. Zeng, N. Chu, D. Soohoo, S. Wong, K. Leung, and J. Zablocki Bioorg. Med. Chem. Lett. 14 2004 973
19. Chlorothienopyrimidines 6 are commercially available, except for 4-chloro-5-phenylthieno[2,3-d]pyrimidine, cf. Supplementary data.
20. T. Kumagai, T. Okubo, H. Kataoka-Okubo, S. Chaki, S. Okuyama, and A. Nakazato Bioorg. Med. Chem. 9 2001 1349
21. In analogy to, for example: W. Yang, Y. Wang, J.Y. Roberge, Z. Ma, Y. Liu, R.M. Lawrence, D.P. Rotella, R. Seethala, J.H.M. Feyen, and J.K. Dickson Jr. Bioorg. Med. Chem. Lett. 15 2005 1225
22. R. Howe, B.S. Rao, B.R. Holloway, and D. Stribling J. Med. Chem. 35 1992 1751
23. https://pharmacology.ricerca.com/Catalog/AssayCatalog/AssayCatalog.aspx, than 'Molecular Packages'.
24. Program packages MOE and Maestro/QikProp.
25. P.A. Procopiou, G.E. Morton, M. Todd, and G. Webb Tetrahedron: Asymmetry 12 2001 2005
26. J. Liu, D. Zhou, X. Jia, L. Huang, X. Li, and A.S.C. Chan Tetrahedron: Asymmetry 19 2008 1824
27. M. Ono, H. Kawashima, A. Nonaka, T. Kawai, M. Haratake, H. Mori, M.-P. Kung, H.F. Kung, H. Saji, and M. Nakayama J. Med. Chem. 49 2006 2725
28. A. Liu, K. Dillon, R.M. Campbell, D.C. Cox, and D.M. Huryn Tetrahedron Lett. 37 1996 3785
29. R. Cribiu, P. Allevi, and M. Anastasia Tetrahedron: Asymmetry 16 2005 3059